Skip to content
Open access

Pathology-guided multimodal transformer predicts postoperative survival benefit from adjuvant chemotherapy in glioma: from DNA damage repair to immune characterization

Oct 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 48 references
Medicine

TL;DR

This model identifies patients unlikely to benefit from standard TMZ chemotherapy, providing a tool for postoperative personalized treatment stratification and optimization of therapeutic strategies in HGGs.

Abstract

Introduction High-grade gliomas (HGGs) are aggressive primary brain tumors with high recurrence rates and poor prognosis. Survival benefit from adjuvant temozolomide (TMZ) varies substantially across patients, and reliable preoperative biomarkers for treatment stratification remain limited. This study aims to develop an interpretable multimodal deep learning model integrating whole-slide histopathological images and multiparametric MRI to preoperatively predict survival benefit from adjuvant TMZ in HGG patients. Methods A Transformer-based multimodal fusion model was proposed. Key tumor regions were identified from whole-slide pathology images via weakly supervised clustering, and pathological features were extracted using attention-based multiple instance learning. Concurrently, 2.5D tumor subregional features were derived from multiparametric MRI sequences. These multimodal features were deeply fused using a Transformer encoder. The model was developed and validated on a multicenter cohort (504 patients), and its biological basis was explored through transcriptomic analysis, gene set enrichment analysis, protein-protein interaction networks, and immune deconvolution. Results The fusion model achieved AUCs of 0.910, 0.861, and 0.833 in the training, internal validation, and external validation cohorts, respectively. Transcriptomic analysis implicated DNA damage repair processes in high-benefit patients, suggesting that enhanced DNA repair capacity may contribute to TMZ sensitivity. Immune deconvolution showed higher M1 macrophage infiltration and lower regulatory T cell abundance in the high-benefit group, consistent with a less immunosuppressive tumor microenvironment. Importantly, low-benefit patients who completed TMZ chemotherapy had shorter survival than those treated with concurrent chemoradiotherapy alone or surgery alone. Conclusion This model identifies patients unlikely to benefit from standard TMZ chemotherapy, providing a tool for postoperative personalized treatment stratification and optimization of therapeutic strategies in HGGs.

Read PDF

Similar papers

#small language model Open access Nov 2026

Multimodal Transformer Integrating CT and Pathology for Postoperative Risk Stratification in Stage I Non-Small Cell Lung Cancer.

The DLRTransformer improved postoperative risk stratification compared with guideline-based risk stratification and identified patients with stage I NSCLC who benefited from adjuvant therapy.

Li-Ying Wang, Yu Zong, Xin-Yu Li et al. · 0 citations
Open access Nov 2026

A deep-learning model based on histological images predicts survival and pathological response to neoadjuvant chemotherapy and chemoimmunotherapy in breast cancer

An artificial intelligence (AI)-based deep-learning model enables accurate inference of a clinically validated immune gene-expression program directly from routine H&E slides and is independently associated with survival and pCR to NACT/NACTIT in eBC.

F. Bertucci, Gwenael Lumet, Mathieu Delattre et al. · 0 citations
Conference Open access Oct 2026

A Digital Twin Framework for Glioblastoma Survival Prediction Using Explainable Machine Learning and Multimodal MRI Radiomic Features

Glioblastoma multiforme (GBM)is one of the most common and lethal forms of brain tumor, with a median overall survival time of being only 12-15 months.GBM is highly heterogeneous meaning that there is considerable variation in tumor characteristics, behavior, and treatment outcomes across patients. This leads to differ...

Asima Majied Wani, M. Chishti, M. A. Wani · 0 citations
Open access Oct 2026

Knowledge-guided Multimodal Learning for Interpretable Prediction of Pathological Complete Response and Survival in Breast Cancer.

PURPOSE Pretreatment estimation of pathological complete response (pCR) to neoadjuvant chemotherapy may support risk stratification and future response-adapted clinical studies in breast cancer. However, existing deep learning approaches often rely on "black-box" visual pattern recognition, suffering from poor interpre...

Wen-Chuan Zhang, Shu-Wan Zhang, Ya-Ni Wei et al. · 0 citations
Sep 2026

GBMM: A graph-based multimodal Mamba model for response prediction in patients with esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.

OBJECTIVE Neoadjuvant immunochemotherapy (NICT) can improve outcomes in advanced esophageal squamous cell carcinoma, but its efficacy varies significantly among patients. Accurately predicting response to NICT before treatment can help identify those who may benefit and avoid ineffective treatment. However, this remain...

Xiao-Qin Zhang, Pei-Xi Peng, Jin-Cheng Chen et al. · 0 citations
Open access Oct 2026

Multi-task deep learning integrating pretreatment MRI and whole slide images predicts induction chemotherapy response and survival in locally advanced nasopharyngeal carcinoma

Predicting response to induction chemotherapy (IC) and overall survival (OS) is critical for optimizing treatment in patients with locally advanced nasopharyngeal carcinoma (LANPC). This study aimed to develop and validate a multi-task deep learning model integrating pretreatment MRI and whole slide images (WSIs) to pr...

Jing Hou, Xiao-Chun Yi, Cong-Rui Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.